Search - tctmd.com

Displaying 141 - 160 of 257

Sort: Relevancy | Date

News Industry News

New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe-simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

February 24, 2015

News Daily News

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

Large Registry Study Suggests Amplatzer Plug Cuts Stroke, Bleeding Risks in A-fib

Todd Neale

February 17, 2015

News Daily News

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

Yael L. Maxwell

January 12, 2015

News Daily News

Meta-analysis Questions One-Size-Fits-All Anticoagulant Strategy in STEMI Patients

L.A. McKeown

November 17, 2014

News Conference News AHA 2014

Vorapaxar Safe in NSTE-ACS But Bleeding Risk Merits 6-Month Delay Before Noncardiac Surgery

Yael L. Maxwell

November 16, 2014

News Conference News TCT 2014

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

September 14, 2014

News Conference News TCT 2014

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

September 13, 2014

News Industry News

Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG

September 02, 2014

News Daily News

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

Todd Neale

August 20, 2014

News Industry News

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

July 23, 2014

News Daily News

HEAT-PPCI Published: Discrepant Finding of Heparin’s Superiority over Bivalirudin in Primary PCI Still Puzzles

Yael L. Maxwell

July 17, 2014

News Industry News

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

July 07, 2014

News Daily News

Strategy of Potent Anticoagulation with Rapid Post-PCI Reversal Appears Safe, Effective

L.A. McKeown

July 03, 2014

News Conference News EuroPCR 2014

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

Yael L. Maxwell

May 21, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

News Industry News

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

May 07, 2014

News Industry News

New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat

May 07, 2014

Advertisement

New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe-simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

Large Registry Study Suggests Amplatzer Plug Cuts Stroke, Bleeding Risks in A-fib

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

Meta-analysis Questions One-Size-Fits-All Anticoagulant Strategy in STEMI Patients

Vorapaxar Safe in NSTE-ACS But Bleeding Risk Merits 6-Month Delay Before Noncardiac Surgery

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

HEAT-PPCI Published: Discrepant Finding of Heparin’s Superiority over Bivalirudin in Primary PCI Still Puzzles

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

Strategy of Potent Anticoagulation with Rapid Post-PCI Reversal Appears Safe, Effective

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content